Fundraising Fox

Lucis

YC X25

Paris, FR · Founded 2025 · 17 employees · Hiring · 9 known investors

Lucis provides personalized health monitoring and guidance by combining laboratory biomarker testing with educational insights and actionable recommendations. The platform helps individuals and healthcare providers identify health risks early through accredited laboratory tests across Europe, with results explained in accessible language.

Also known as Lucis (ex-Zero Health) · Zero Health · Lucis

Founders & leadership· Y Combinator alumni (X25)

Lucis was founded in 2025 by Max Berthelot and Baptiste Debever.

MBMax Berthelot
Max Berthelotin𝕏FounderMax Berthelot founded and serves as CEO of Lucis, a health technology platform focused on the European market.
BDBaptiste Debever
Baptiste Debeverin𝕏Founder & CTOBaptiste Debever is a French engineer and repeat founder who previously worked as an engineer at Gorgias. He is now building an AI-powered health navigation platform.
JDJulien Do Vale
Julien Do ValeM.D., MSc, Chief Medical Officer
EREugenia Rodriguez
Eugenia RodriguezM.D., Clinical & Product Lead

Board

AAAntoine Andremont
Antoine AndremontM.D., PHD, President of the scientific board
JBJérémy Bos
Jérémy BosMD, MSc, Specialist in public health and clinical epidemiology

Investors · 9

Also in the syndicate · 3

Céline Lazorthesinvestors behind RunnaManu Lecomte

Funding

SEC filings, press & company announcements

$20M disclosed across 1 of 3 rounds · 2025–2026

Source: company announcements and press reports — follow each round's link for the claim.

Company profile

researched Aug 2026

Lucis is a Paris-based preventive health company that pairs laboratory biomarker testing with an AI-driven health companion application. Members complete a health questionnaire covering goals, symptoms, history and lifestyle, optionally connect wearables, and are tested twice a year at partner laboratories, with blood, urine and saliva collected in a single visit. The panels cover more than 100 biomarkers on the first comprehensive assessment and 60+ on a six-month follow-up check, grouped into categories such as kidney health, inflammation, nutrients, metabolic, cardiac, liver health, minerals, adrenal function, thyroid hormones, bone health, sexual hormones, iron metabolism, hematology, immunity and prostate markers, and scored across 11 body systems.

Results are presented in a private dashboard with simplified wellness indices and plain-language explanations, alongside a personalized action plan produced by healthcare professionals spanning nutrition, supplementation, sleep, physical activity, environment and mental health. The AI companion combines biomarker results, longitudinal data and medical context, refreshing recommendations as new data arrives; outputs are reviewed by physicians. Lucis states that its content is educational and does not replace medical diagnosis, prescription or advice, and positions the structured data as a way for doctors to surface risks early and prepare appointments.

The company reports GDPR compliance, ISO 27001 certification for information security and HDS-certified hosting. Membership is open to people aged 18 and over.

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Annual membership price (Lucis Care)Jan 2026490 EUR/year
Biomarker tests deliveredMay 20261,000,000 tests
Biomarkers analyzed (first assessment)May 2026110 biomarkers
EmployeesMay 202620 people
HeadcountAug 202637
Members / usersMay 202610,000 users
Partner laboratories in EuropeJan 2026450 labs
Physicians providing clinical oversightMay 202610 physicians
Total funding raisedMay 2026$28M
Trustpilot ratingJan 20264.5 out of 5
Users improving at least three biomarkers within six months (without medication)May 202675%
Users opting to retestMay 2026More than 80%
Users with at least one biomarker outside optimal range at initial testingMay 202699.9%

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Competitors · 2

by search overlap

Companies competing with Lucis for the same Google search keywords, organic and paid, via search-intersection analysis.

Timeline · 3

launches, deals, and filings
May 2026
Lucis raises $20M Series A led by Singular

Lucis announced a $20 million Series A led by Singular with participation from General Catalyst, Y Combinator and angel investors, bringing total funding to $28M. Proceeds are earmarked for European expansion and development of its AI health companion app.

$20M source ↗

May 2026
Laboratory partnerships with Eurofins and Randox

Lucis reported partnerships with laboratory groups including Eurofins and Randox to support sample collection and analysis.

source ↗

Jan 2026
Planned expansion into Spain, Germany and Italy

Lucis stated it plans to launch in Spain, Germany and Italy by the end of 2026, adding to existing operations in France, the UK, Ireland and Portugal.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

In the news

Research sources · 8

primary sources listed

8 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Lucis do?
European preventive health platform combining 110+ blood biomarker tests with an AI companion app and physician oversight.
Who founded Lucis?
Lucis was founded by Max Berthelot, Baptiste Debever in 2025.
Who are Lucis's investors?
Lucis's investors include Circle & Co., Clover, North South Ventures, Y Combinator, General Catalyst, Singular.
How much funding has Lucis raised?
Lucis has disclosed $20M raised across 1 of its 3 known rounds.
Where is Lucis headquartered?
Lucis is headquartered in Paris, FR.